Salestools LogoSalestools
Agentes IA de Salestools
Soluciones
Recursos
Empresa
Precios
Salestools Logo

Salestools

El agente IA #1 para equipos de ventas y Go-to-Market. Vende más, más rápido, con menos esfuerzo.

Producto

  • Agentes de ventas IA
  • Datos de intención
  • Datos tecnológicos
  • Seguimiento de visitantes
  • Co-Pilot
  • Venta social

Soluciones

  • Servicio al cliente
  • Comercio electrónico
  • SaaS
  • Empresarial
  • Pequeña empresa

Recursos

  • El informe
  • Documentación
  • Referencia de API
  • Centro de ayuda
  • Blog
  • Casos de estudio
  • Webinars

Empresa

  • Acerca de
  • Carreras
  • Prensa
  • Contacto
  • Socios

Nuestras ubicaciones

  • Nueva York, HQ
  • Bucarest, laboratorio de investigación IA
  • Zug, Suiza

© 2025 Salestools. Todos los derechos reservados.

Términos de datos y seguridadPolítica de privacidadTérminos de servicio
Todos los sistemas operativos
Salestools LogoSalestools
Agentes IA de Salestools
Soluciones
Recursos
Empresa
Precios
Back to The Report
Fundraising

Imperva

Imperva Raises $110M in Series E

2002
Founded
1200+
Employees
Redwood Shores, CA
Updated November 1, 2024
2 min read

Quick Facts

Imperva Raises $110M in Series E


Imperva has successfully raised $110M in a Series E at a $1.15B valuation led by Greylock Partners, Lightspeed.


Company Overview


Imperva is a Cybersecurity company headquartered in Redwood Shores, CA, founded in 2002 with 1200+ employees.


Application and data security


Fundraising Details


  • Amount Raised: $110M
  • Round Type: Series E
  • Valuation: $1.15B
  • Date: 2024-11-01
  • Investors: Greylock Partners, Lightspeed

About Imperva


Application and data security The company is positioned in the Cybersecurity sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: Redwood Shores, CA
  • Founded: 2002
  • Team Size: 1200+
  • Industry: Cybersecurity

What This Means


This funding round demonstrates strong investor confidence in Imperva's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Cybersecurity sector continues to attract significant investment as companies innovate to meet evolving market demands. Imperva's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $1.15B valuation marks an important milestone for Imperva, positioning the company among notable players in the Cybersecurity industry.


Looking Ahead


With this new capital, Imperva is well-positioned to execute on its growth strategy and continue building innovative solutions in the Cybersecurity space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-11-01. For more information about Imperva, visit their headquarters at Redwood Shores, CA.

Topics

Fundraising(2912)Cybersecurity(452)Series EImperva

About the Author

Fundraising News Team
Fundraising News Team
Tracking the latest funding rounds and investment news

Related Company Reports

Fundraising
Harvey AI

Harvey AI Raises $160 million in Series F

Harvey AI, a AI Software company based in San Francisco CA, has raised $160 million in Series F at a $8 billion valuation led by Andreessen Horowitz.

Market Intelligence Team
Market Intelligence Team
Dec 4, 2025
0 min read•160 million
Fundraising
7AI

7AI Raises $130 million in Series A

7AI, a Cybersecurity company based in Boston MA, has raised $130 million in Series A at a $700 million valuation led by Index Ventures.

Market Intelligence Team
Market Intelligence Team
Dec 4, 2025
0 min read•130 million
Fundraising
TRIANA Biomedicines

TRIANA Biomedicines Raises $120 million in Series B

TRIANA Biomedicines, a Biotechnology company based in Lexington MA, has raised $120 million in Series B at a Undisclosed led by Ascenta Capital.

Market Intelligence Team
Market Intelligence Team
Dec 3, 2025
0 min read•120 million